144 related articles for article (PubMed ID: 33098372)
21. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
23. The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
Brajtbord JS; Leapman MS; Cooperberg MR
Eur Urol; 2017 May; 71(5):705-709. PubMed ID: 27616723
[TBL] [Abstract][Full Text] [Related]
24. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.
Inamoto T; Azuma H; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Kazuhiro S; Naito S; Namiki M; Nishimura K; Hirao Y; Usami M; Murai M; Akaza H;
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1197-204. PubMed ID: 24676427
[TBL] [Abstract][Full Text] [Related]
25. Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity.
Campbell JM; O'Callaghan ME; Raymond E; Vincent AD; Beckmann KR; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti KL
Clin Genitourin Cancer; 2017 Dec; 15(6):629-634.e8. PubMed ID: 28576416
[TBL] [Abstract][Full Text] [Related]
26. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
27. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.
Matsuoka T; Kawai K; Kimura T; Kojima T; Onozawa M; Miyazaki J; Nishiyama H; Hinotsu S; Akaza H
J Cancer Res Clin Oncol; 2015 Apr; 141(4):759-65. PubMed ID: 25326347
[TBL] [Abstract][Full Text] [Related]
29. Gleason score predicts androgen independent progression after androgen deprivation therapy.
Benaim EA; Pace CM; Roehrborn CG
Eur Urol; 2002 Jul; 42(1):12-7. PubMed ID: 12121723
[TBL] [Abstract][Full Text] [Related]
30. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
31. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
33. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
Jain S; Lyons CA; Walker SM; McQuaid S; Hynes SO; Mitchell DM; Pang B; Logan GE; McCavigan AM; O'Rourke D; McArt DG; McDade SS; Mills IG; Prise KM; Knight LA; Steele CJ; Medlow PW; Berge V; Katz B; Loblaw DA; Harkin DP; James JA; O'Sullivan JM; Kennedy RD; Waugh DJ
Ann Oncol; 2018 Jan; 29(1):215-222. PubMed ID: 29045551
[TBL] [Abstract][Full Text] [Related]
34. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
35. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
[TBL] [Abstract][Full Text] [Related]
36. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
37. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
38. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
39. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
40. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
